RxDoctor Payments Data

Rishi Anand

Endocrinology, Diabetes & Metabolism · Bensalem, PANPI 1457599300

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $37,500 of the $41,469 with a category attached, or 90.4%. AstraZeneca accounts for 85.3% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $28,130 and has fallen 99.9% since, to $23 in 2024.

$41,469in general payments, 2019–2025

Across 152 payments — averaging $272.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$35K
  • Portola Pharmaceuticals, LLC$4K
  • Novo Nordisk$442
  • Lilly USA, LLC$225
  • Companion Medical, Inc.$109
  • Xeris Pharmaceuticals, Inc.$106
  • plus $789 from 19 others

What the payments were for

  • Speaking & faculty fees$37,50090%
  • Travel & lodging$1,2853%
  • Food & beverage$2,6456%
  • Education$380%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,469 in reported general payments places this provider in the 85th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania

Other endocrinology, diabetes & metabolism in Bensalem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →